The present invention relates to the use of novel derivatives of general formula (I) ##STR00001## in which R3 is a (1-6C)alkyl, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, COOR1, SO.sub.2R1, C(.dbd.NH)R1 or C(.dbd.NH)NR1 radical; R5, R6 and R7 are, independently of one another, chosen from the following radicals: halogen, CN, NO.sub.2, NH.sub.2, OH, OR8, COOH, C(O)OR8, --O--C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO.sub.2R8, NHSO.sub.2R8, SO.sub.2NR8R9, --O--SO.sub.2R8, --SO.sub.2--O--R8, trifluoromethyl, trifluoromethoxy, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl, adamantyl or polycycloalkyl, to treat a disease selected from the group consisting of: neurodegenerative diseases, strokes, cranial and spinal traumas and peripheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovaries syndrome, syndrome X, immunodeficiency and cancer.

 
Web www.patentalert.com

< N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators

> Use of tellurium containing compounds as nerve protecting agents

> Sphingolipid-derived pharmaceutical compositions

~ 00565